Crystal structures of the transpeptidase domain of the Mycobacterium tuberculosis penicillin‐binding protein PonA1 reveal potential mechanisms of antibiotic resistance by Filippova, Ekaterina V. et al.
Crystal structures of the transpeptidase
domain of the Mycobacterium
tuberculosis penicillin#binding
protein PonA1 reveal potential
mechanisms of antibiotic resistance
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Filippova, Ekaterina V., Karen J. Kieser, Chi#Hao Luan, Zdzislaw
Wawrzak, Olga Kiryukhina, Eric J. Rubin, and Wayne F. Anderson.
2016. “Crystal structures of the transpeptidase domain of the
Mycobacterium tuberculosis penicillin#binding protein PonA1
reveal potential mechanisms of antibiotic resistance.” The Febs
Journal 283 (12): 2206-2218. doi:10.1111/febs.13738. http://
dx.doi.org/10.1111/febs.13738.
Published Version doi:10.1111/febs.13738
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:31731894
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
EDITOR’S CHOICE
Crystal structures of the transpeptidase domain of the
Mycobacterium tuberculosis penicillin-binding protein
PonA1 reveal potential mechanisms of antibiotic resistance
Ekaterina V. Filippova1,2,3, Karen J. Kieser4, Chi-Hao Luan2,5, Zdzislaw Wawrzak6,
Olga Kiryukhina1,2,3, Eric J. Rubin4,7 and Wayne F. Anderson1,2,3
1 Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
2 Midwest Center for Structural Genomics (MCSG), Biosciences Division, Argonne National Laboratory, Argonne, IL, USA
3 Center for Structural Genomics of Infectious Diseases (CSGID), Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
4 Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, MA, USA
5 High Throughput Analysis Laboratory and Department of Molecular Biosciences, Northwestern University, Evanston, IL, USA
6 Life Science Collaborative Access Team, Synchrotron Research Center, Northwestern University, Evanston, IL, USA
7 Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA
Keywords
b-lactams; antibiotic resistance; PBP;
PonA1; transpeptidase domain; tuberculosis
Correspondence
W. F. Anderson, Department of
Biochemistry and Molecular Genetics,
Feinberg School of Medicine, Northwestern
University, Chicago, IL 60611, USA
Fax: +312 503 5349
Tel: +312 503 1697
E-mail: wf-anderson@northwestern.edu
(Received 28 January 2016, revised 30
March 2016, accepted 15 April 2016)
doi:10.1111/febs.13738
Mycobacterium tuberculosis is a human respiratory pathogen that causes the
deadly disease tuberculosis. The rapid global spread of antibiotic-resistant
M. tuberculosis makes tuberculosis infections difficult to treat. To overcome
this problem new effective antimicrobial strategies are urgently needed. One
promising target for new therapeutic approaches is PonA1, a class A peni-
cillin-binding protein, which is required for maintaining physiological cell wall
synthesis and cell shape during growth in mycobacteria. Here, crystal struc-
tures of the transpeptidase domain, the enzymatic domain responsible for peni-
cillin binding, of PonA1 fromM. tuberculosis in the inhibitor-free form and in
complex with penicillin V are reported. We used site-directed mutagenesis,
antibiotic profiling experiments, and fluorescence thermal shift assays to mea-
sure PonA1’s sensitivity to different classes of b-lactams. Structural compar-
ison of the PonA1 apo-form and the antibiotic-bound form shows that
binding of penicillin V induces conformational changes in the position of the
loop b40-a3 surrounding the penicillin-binding site. We have also found that
binding of different antibiotics including penicillin V positively impacts protein
stability, while other tested b-lactams such as clavulanate or meropenem
resulted in destabilization of PonA1. Our antibiotic profiling experiments indi-
cate that the transpeptidase activity of PonA1 in both M. tuberculosis and
M. smegmatis mediates tolerance to specific cell wall-targeting antibiotics, par-
ticularly to penicillin V and meropenem. Because M. tuberculosis is an impor-
tant human pathogen, these structural data provide a template to design novel
transpeptidase inhibitors to treat tuberculosis infections.
Database
Structural data are available in the PDB database under the accession numbers 5CRF and 5CXW.
Abbreviations
FTS, fluorescence thermal shift; PBP, penicillin-binding protein; TB, tuberculosis; TG-, transglycosylase domain mutant; TP-, transpeptidase
domain mutant.
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Introduction
Mycobacterium tuberculosis is a bacterial pathogen of
the human respiratory system that primarily infects
lungs but could also infect other parts of the body
including kidney, spine, and brain. Tuberculosis (TB)
infection is fatal for ~ 1.5 million people worldwide
each year according to the World Health Organiza-
tion and remains silent within 90% of the infected
population [1]. Emergence of antibiotic-resistant
M. tuberculosis bacteria has become a serious health
problem during the last 40 years. In order to control
and treat TB disease, the development of new effec-
tive drugs is urgently needed.
Mycobacterium tuberculosis has a complicated cell
wall architecture compared to other antibiotic resistant
bacteria [2–4]. The complexity of the cell wall is consid-
ered to be one of the reasons for the bacterium’s natural
tolerance to antibiotics. One major cell wall component
is peptidoglycan. The mutations of proteins involved in
peptidoglycan synthesis in M. tuberculosis consequently
lead to antibiotic resistance [5]. The peptidoglycan layer
is formed by glycan chains of b-(1,4) linked N-acetylglu-
cosamine and N-acetylmuramic acid which are addi-
tionally crosslinked by 3,3 or 4,3 transpeptide bonds
between short amino acid fragments of alanine, gluta-
mate, and diaminopimelic acid residues. In mycobacte-
ria, the 3,3 crosslinks are generated in equal abundance
in all phases of bacterial growth by the L,D-transpepti-
dases [6,7]. The classical 4,3 crosslinks are formed
during the exponential phase of growth by the D,D-
transpeptidase activity of penicillin-binding proteins
(PBPs) [8]. The 4,3 transpeptidase activity could be
easily inhibited by penicillin or other b-lactam antibi-
otics by forming a stable covalent complex with the ser-
ine at the active site of the PBP [9]. PBPs have not
traditionally been chosen as primary drug targets for
M. tuberculosis because b-lactams are very susceptible
to degradation by endogenous bacterial b-lactamases;
however, recent reports indicate some level of efficacy
against drug-sensitive and even drug-resistant M. tuber-
culosis strains [10]. A more recent study in Escherichia
coli indicates that b-lactams do not only inhibit
transpeptidase activity of PBPs but also induce degrada-
tion of the newly formed peptidoglycan chains, leading
to systemic toxicity [11]. Therefore, investigating PBPs
from M. tuberculosis may provide novel opportunities
for the development of new antibiotics that would be
resistant to b-lactamase cleavage and would simultane-
ously target multiple cellular proteins involved in pepti-
doglycan biosynthesis.
Mycobacterium tuberculosis possesses only two class
A PBPs, PonA1 and PonA2, that contain both a
transglycosylase domain involved in polymerization of
the polyglycan chains and a transpeptidase domain,
the enzymatic domain responsible for binding of peni-
cillin [12,13]. Different studies indicate that PonA1
and PonA2 play a complex role in bacterial physiology
and have an unusual hypersusceptibility to b-lactam
antibiotics, suggesting that novel therapeutic develop-
ment could optimally target these enzymes [14–17]. To
understand the role of class A PBPs in mycobacterial
peptidoglycan biology, we examined PonA1 from the
M. tuberculosis strain H37Rv. PonA1 is a high molec-
ular weight 71 kDa, two-domain protein that contains
a noncleavable signal peptide at the N terminus. The
N-terminal signal peptide of PonA1 is phosphorylated
and was identified as a substrate for the serine–thre-
onine protein kinase PknB [15,18]. The peptidoglycan
transglycosylase domain is homologous to PBP1 from
E. coli [19] and catalyzes the ligation of N-glycolyl
muramic acid from the polyglycan sacculus to N-acetyl
glucosamine from amphipathic peptidoglycan precur-
sor molecules (lipid II). The C-terminal domain of
PonA1 crosslinks the penultimate D-alanine to the
D-meso-diaminopimelic acid between parallel peptido-
glycan strands. PonA1 localizes to the poles and septa
of M. smegmatis and is required for maintaining nor-
mal cell length in both M. tuberculosis and M. smeg-
matis [15,20,21]. Changes to the level of PonA1
protein result in a structurally abnormal cell shape,
suggesting that PonA1 is critical for maintaining physi-
ological cell wall synthesis and cell shape during
growth. PonA1 regulates essential RipA peptidoglycan
hydrolase activity and binds to the RipA endopepti-
dase domain at the end of PonA1’s C-terminal
transpeptidase domain [20]. Additionally, recent work
shows that PonA1 activity impacts antibiotic tolerance
in mycobacteria [5]. Altering PonA1 transpeptidase or
phosphorylation activity affects bacterial growth in the
presence of the antibiotic teicoplanin, which targets
peptidoglycan biosynthesis [15].
In this study, we describe the high-resolution crystal
structure of the PonA1 transpeptidase domain from
the M. tuberculosis virulent strain H37Rv in ligand-
free form and in complex with penicillin V. We charac-
terize the structural details and penicillin-binding site.
Furthermore, using site-directed mutagenesis and
antibiotic profiling, we provide evidence that PonA1’s
transpeptidase activity in both M. tuberculosis and
M. smegmatis mediates tolerance to different classes of
b-lactams. Loss of PonA1’s transpeptidase activity ren-
ders cells more susceptible to b-lactams, especially to
meropenem and penicillin V. Additionally, we tested
the stability of PonA1 in the presence of different
classes of b-lactams by fluorescence thermal shift
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(FTS) assays. We find that different antibiotics have
different impact on the folding of PonA1. FTS data
show that binding and formation of the acyl-enzyme
by compounds like carbenicillin or penicillin V result
in positive Tm shifts, while others like clavulanate or
meropenem give negative Tm shifts, indicating that
they induce a more destabilized conformation of
PonA1. The structure of PonA1’s transpeptidase
domain in complex with penicillin V provides a start-
ing point to understand the mechanism underlying the
development of antibiotic resistance in M. tuberculosis
and to design novel transpeptidase inhibitors, which
hold great potential for the treatment of TB disease.
Results
Overall structure of PonA1’s transpeptidase
domain
Four PonA1 molecules in the asymmetric unit of the
inhibitor-free form share a similar structure with an
average root-mean-square deviation (RMSD) value of
0.2 A calculated between the Ca atoms of their main
chains. Gel filtration chromatography and analysis by
the PISA server [22] suggest that the biological unit of
PonA1 is a monomer (data not shown). Crystallized
PonA1 molecules (residues 249–643) contain the
transpeptidase domain and one small adjacent domain
at the N terminus of the transpeptidase domain
(Figs 1A and 2). The first 156 residues that form part
of the N-terminal glycosyltransferase domain and 33
residues at the C terminus of PonA1 were not
observed in the protein structure. These modifications
could be due to protein degradation and/or structural
disorder. In the structure, the PonA1 molecule has a
unique unstructured C terminus that contains a pro-
line-rich region. This region forms an exposed long
hydrophobic tail (Fig. 1B), suggesting that it may be
involved in the protein–protein interactions that have
been suggested by previous studies [23]. The small
adjacent N-terminal segment of the transpeptidase
domain comprises two a-helices [a1n (250–268) and
a2n (270–276)] and a three-stranded [b1n (280–284),
b2n (480–486), and b3n (490–495)] antiparallel b-sheet
(Figs 1A and 2). The PonA1 transpeptidase (or peni-
cillin-binding domain) resembles other PBPs secondary
structure: PBP1 of class A from Staphylococcus pneu-
monia (RMSD of 1.9 A) [24,25], the transpeptidase
domain of PBP2 from Neisseria gonorroeae (RMSD of
2.00 A) [26], class A PBP1 from Pseudomonas
aeruginosa (RMSD of 1.65 A) [27,28], and PBP4 from
Listeria monocytogenes (RMSD of 2.01 A) [29]. A cleft
in the middle of the domain contains the active site.
The cleft divides the transpeptidase domain of PonA1
into two subdomains (Figs 1A and 2). One subdomain
has a/b fold and contains an antiparallel b-sheet sur-
rounded by a-helices in a following order: a1 (286–
302), b1 (307–316), b2 (321–326), b10 (341–343), b50
(473–475), b60 (503–505), a8 (520–525), b3 (537–545),
b4 (550–560), b5 (563–572), and a9 (590–605). The
second subdomain has an a-helical structure with six
a-helices: a2 (349–358), a3 (391–397), a4 (399–410), a5
Fig. 1. Structure of the transpeptidase domain of PonA1. (A) Ribbon diagram of the C-terminal transpeptidase domain of PonA1 monomer
from Mycobacterium tuberculosis. The small adjacent N-terminal segment of the PonA1 transpeptidase domain is colored in blue and cyan.
The PonA1 penicillin-binding domain is colored in green. Residues of the hydrophobic C-terminal segment and cysteine residues are shown
as a ball-and-stick model, where carbon atoms are in green (or blue for cysteines), nitrogen atoms in blue, oxygen atoms in red, and sulfur
atoms in pink. Residues composing conserved motifs in the penicillin-binding pocket of PBPs are shown as a cylinder model in crimson.
The secondary structure elements are labeled. (B) Electrostatic surface representation. The surface is colored by surface potential charge
from negative in red to positive in blue. (C) Comparison of PonA1 structures with (gold) and without penicillin V (green). Penicillin V is
shown as a cylinder model in dark purple. The disposition of the loops in superimposed structures is marked with arrows.
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(413–425), a6 (458–471), and a7 (507–519). Addition-
ally, the second subdomain contains a long loop with
three short b strands, b20 (364–368), b30 (371–373),
and b40 (376–378), that forms part of the inhibitor-
binding pocket. The conformation of this loop is held
by disulfide bond between Cys386 and Cys389
(Fig. 1A).
Fluorescence thermal shift assays
To investigate whether certain drugs may impact the
stability of the protein, we determined thermal denatu-
ration curves using FTS assays with different deriva-
tives of b-lactam antibiotics. Effects of 23 antibiotics
on the denaturation temperature of PonA1 were deter-
mined (Fig. 3). The data show that hetacillin
(DTm = 3.0 °C), carbenicillin (DTm = 2.2 °C), dicloxa-
cillin (DTm = 1.9 °C), penicillin V (DTm = 1.6 °C), or
cefotaxime (DTm = 1.6 °C) shifts the Tm of PonA1 by
more than 1° in the positive direction, while nafcillin
(DTm = 2.0 °C), clavulanate (DTm = 2.7 °C), and
meropenem (DTm = 3.8 °C) cause significant Tm
shifts in the negative direction. The data shown are for
PonA1 at 2.8 lM and the antibiotics at 5 lM.
The significant transition temperature shift at this
low drug to protein ratio (1.8–1) indicates specific
binding of these antibiotics to PonA1. Furthermore,
carbenicillin gave rise to a similar positive Tm shift as
penicillin V, cefotaxime, and dicloxacillin, while com-
pounds such as clavulanate, meropenem, and nafcillin
exhibited negative Tm shifts, indicating that these com-
pounds make PonA1 less stable in these conditions.
Fig. 2. PonA1 domain composition and
protein secondary structure assignment.
(A) Functional domains of PonA1 protein.
The analysis of PonA1 sequence was
performed on the Pfam database (http://
pfam.xfam.org/). (B) PonA1 sequence of the
crystallized transpeptidase domain. The
secondary structure elements are shown
above the sequence. The stars below the
sequence indicate the first and last residue
that was observed in the structure of the
crystallized PonA1 domain.
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While b-lactam compounds induced ~ 10 °C Tm shift
for other PBP proteins we studied (data not shown),
the largest shift we observed for PonA1 was < 3.5 °C.
Catalytic site and PonA1–penicillin V interactions
Similar to all known b-lactam-binding proteins, the
PonA1 transpeptidase domain contains three con-
served sequence motifs: SxxK (which contains the cat-
alytic serine), SxN, and KTG at the penicillin-binding
cleft [8,9]. The SxxK motif comprising residues
Ser345, Ser346, Phe347, and Lys348 is located at the
N terminus of the helix a2 and contains two impor-
tant residues for catalysis in PBPs: Ser345 and
Lys348. Ser345 is acylated by the substrate and situ-
ated at the center of the catalytic site. Lys348 is
thought to enhance the nucleophilicity of the serine.
The SxN motif comprising residues Ser398, Leu399,
and Asn400 is located on the loop between helices a3
and a4. The KTG motif comprising residues Lys539,
Thr540, and Gly541 is situated on the strand b3 of
the PonA1 transpeptidase domain. In the inhibitor-
free PonA1 structure, the Ser345 hydrogen bonds with
Lys348, Glu382, and Thr540 and through a water
molecule with Ser398. At the penicillin-binding site of
the PonA1 structure, Lys348 hydrogen bonds with
Asn400 from the SxN motif. We identify another
hydrogen bond between Lys539 and Ser398 from the
SxN motif. Despite the similarity in the position of
the three conserved motifs within the active site, the
rate of acylation of b-lactams varies considerably in
different PBPs [30–33]. This suggests that the architec-
ture of the antibiotic-binding pocket and adjacent
loops plays an important role in the activity of differ-
ent PBPs and likely influences PonA1’s interaction
with inhibitors.
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Fig. 3. Modulation of thermal stabilities of
PonA1 by different classes of antibiotics as
indicated by FTS determined DTm. The
ordinate is calculated as the difference
between the Tm values of PonA1 at
presence and absence of antibiotics:
cefazolin (1), methicillin (2), cloxacillin (3),
nafcillin (4), amoxicillin (5), ampicillin (6),
hetacillin (7), dicloxacillin (8), oxacillin (9),
penicillin G (10), penicillin V (11),
cephalothin (12), cephapirin (13), cephalexin
(14), cefoxitin (15), cefotaxime (16),
cefadroxil (17), cefoperazone (18),
cefhaloridine (19), cefonicid (20), clavulanate
(21), carbenicillin (22), meropenem (23). The
data shown are for PonA1 at 2.8 lM and
the antibiotics at 5 lM. Of the 23
derivatives of b-lactam antibiotics, nafcillin,
clavulanate, and meropenem give rise to
significant negative Tm shift indicating that
these compounds make PonA1 less stable.
In contrast, hetacillin, carbenicillin,
dicloxacillin, and penicillin V induces the Tm
shift of PonA1 in the positive direction as
observed for other PBP proteins.
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The high-resolution crystal structure of PonA1 in
the penicillin V acylated form was determined and
contained one protein molecule (residues 249–628) in
the asymmetric unit. The part of the N-terminal glyco-
syltransferase domain (156 residues) and C terminus
(51 residues) were missing in the structure due to pro-
tein degradation and/or disorder. We calculated
RMSD values between the Ca atoms of PonA1 mono-
mers in the apo-form and PonA1 monomer in the
ligand-bound structure. The average RMSD value was
0.5 A. Conformational changes with RMSD > 0.8 A
were observed in the position of the loops between
b40-a3 (loop with disulfide bridge), a5-a6, b3-b4, b5-a9
(in monomer C of the apo-form), and b3n-b60 (in
monomer A of the apo-form) as well as in the position
of the small adjacent domain at the N terminus of the
transpeptidase domain (Fig. 1C). Another change that
was observed was in the position of the C-terminal
proline-rich tail in all monomers of PonA1 (Fig. 1C).
To investigate if packing interactions between adjacent
monomers in the crystal lattice were responsible for
conformational differences in the structures, we ana-
lyzed their crystal contacts. In the crystal lattice,
PonA1 monomers were very tightly packed with Mat-
thews coefficients Vm = 1.81 and Vm = 2.17 for the
inhibitor-free form and penicillin V-bound form,
respectively. The contacts between the PonA1 mono-
mers and symmetry-related monomers in ligand-free
and penicillin V-bound structures with Van der Waals
interactions < 4.6 A were calculated with the program
CONTACT (CCP4 support program [34]). The analysis
indicated that all monomers have different contact
areas with symmetry-related monomers. Most of the
conformational changes including the N-terminal
adjacent domain and C-terminal proline-rich tail have
contacts with symmetry equivalent monomers in one
or both structures. However, the position of the loop
between b40-a3 surrounding the active site was not
associated with crystal packing and was most likely
affected by reaction with the penicillin V (Fig. 4A).
The disposition of the loop b40-a3 in the PonA1
monomers has the largest RMSD value ~ 3 A (calcu-
lated average value). In two monomers (B and D) of
the apo-form structure, this loop is partially disordered
due to its mobility.
At the binding cleft, penicillin V forms an acyl–
enzyme complex through the covalent bond between
the OG atom of Ser345 and the C6 atom of the b-
lactam ring (Fig. 4A and 4B). The carboxyl group of
the thiazolidine ring forms hydrogen bonds with OG1
atoms of Thr540 and Thr542 located on the b3 strand,
and through a water molecule with the nitrogen of the
main chain and the OG atom of the side chain of
Ser589 on the loop b5-a9 (Fig. 4C). The N7 atom of
the thiazolidine ring of penicillin V hydrogen bonds
with the OG atom of Ser398 located on helix a3. The
N4 and O18 atoms of the acyl side chain of penicillin
V interact with the O atom of the main chain of
Thr542 of b3 and the ND2 atom of the side chain of
Asn400 of a4, respectively. Other interactions occur
between the O1 and O18 atoms of penicillin V and
Thr379 of b40, Ser381 of b40, and Ser398 of a4 residues
through water molecules (Fig. 4C). Therefore, struc-
tural analysis of PonA1 in an antibiotic-bound and
free form suggests that positioning of the R group of
penicillin V at the active site is accompanied by con-
formational change of the loop b40-a3 that widened
the penicillin-binding pocket (Fig. 4A).
Fig. 4. Penicillin V-binding site. (A and B) Comparison of PonA1 active site with (gold) and without (green) penicillin V. Penicillin V covalently
bound to Ser345 is presented as a ball-and-stick model. Residues of the penicillin-binding site are shown as a cylinder model, where carbon
atoms are in gray, nitrogen atoms in blue, oxygen atoms in red, and sulfur atoms in yellow. At the protein active site of the liganded
structure, penicillin V is shown in the electron density omit map. (C) LigPlot diagram of penicillin V-binding site. Hydrogen bonds for
antibiotic on the LigPlot+ are shown as black broken lines. In the LigPlot+ diagram, water molecules are colored in brown, oxygen atoms in
red, carbon atoms in black, nitrogen atoms in blue, and sulfur in yellow.
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Antibiotic profiling experiments
PonA1’s interaction with small molecules occurs in the
inhibitor cleft, which includes its active site serine.
Because of the importance of PonA1’s active site in
cell wall biosynthesis and cell growth, we hypothesized
that PonA1’s active site serine plays a key role in the
protein’s interactions with small molecules during cell
growth. To test the importance of PonA1’s active site
for interaction with antibiotics, we generated M. tu-
berculosis and M. smegmatis mutants of the transpep-
tidase active site. Coupling these genetic mutants with
several derivatives of b-lactams, we assessed the
efficacy of particular PBP-targeting antibiotics in
M. tuberculosis and M. smegmatis (Fig. 5A). For both
M. tuberculosis and M. smegmatis, loss of PonA1’s
transpeptidase activity rendered cells more susceptible
to b-lactams, specifically to carbenicillin and merope-
nem (Fig. 5A). It is possible that the observed differ-
ence in antibiotic tolerance may be due to altered
effective antibiotic concentration for the remaining
PBPs in the cell (because transpeptidase mutant
PonA1 no longer covalently binds transpeptidase inhi-
bitors). However, our previous work demonstrated
that M. tuberculosis cells that lack PonA1 and PonA2
exhibit differential susceptibility to cell wall-targeting
antibiotics, including transpeptidase inhibitors. Thus,
although these proteins are homologous, their distinct
Fig. 5. In vitro antibiotic efficacy experiments. (A) The indicated Mycobacterium tuberculosis H37Rv strains were grown in the presence of
carbenicillin and clavulanate (left panel) or meropenem (right panel) at the indicated concentrations. Bacterial survival in the presence of
antibiotic was calculated in comparison to untreated bacterial cells. Wild-type PonA1, wt; TG-mutant PonA1, TG-; TP-mutant PonA1, TP-;
double TG- and TP-mutant PonA1, TG-TP-. Data were collected in duplicate for each strain and are representative of two experiments. Error
bars represent SD. The asterisk indicates P-value of < 0.05 and was determined by an unpaired, two-tailed t-test. (B) M. smegmatis mc2155
strains expressing wild-type PonA1 (wt, nonoutlined squares) or transpeptidase mutant PonA1 (TP-, outlined circles) were grown in the
presence of penicillin V and clavulanate (left panel) or meropenem (right panel) at the indicated concentrations. Untreated control cells are
shown in gray for both strains. Data were collected in triplicate (for carbenicillin data) or duplicate (for penicillin V data) for each strain and
are representative of two experiments. Error bars represent SEM.
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physiological roles in mycobacterial cell wall biology
result in different susceptibility to cell wall-active
drugs [35].
Interestingly, cell growth plateaued at different times
when M. smegmatis cells were treated with penicillin V
compared with meropenem. The PonA1 transpeptidase-
inactivated cells exhibit a substantial delay in growth at
a range of penicillin V concentrations when compared
to wild-type control (Fig. 5B). At 1 lgmL1, the TP
cells never recover. These data suggest that cells lacking
PonA1’s transpeptidase activity grow much less robustly
in the presence of penicillin V or meropenem.
We observed that when we treat cells that encode an
allele of ponA1 wherein both enzymatic domains are
inactivated (Fig. 5A, TG-TP-) with meropenem, the
survival rate is almost the same as the single TG-
mutant. This may correlate with other cell biology
data that show the expression of a TP allele is more
toxic than a TG-allele or a TG-TP-allele (and that the
latter phenocopy each other) if the cells also undergo
inhibition of crosslinking [11,15]. One model in E. coli
explains that this may be due to cells experiencing a
buildup of uncrosslinked glycan strands [15]. However,
the carbenicillin data do not fit this model; the TG-
TP-cells phenocopy the TP-cells. That could be related
to the frequency of 4,3 and 3,3 crosslinks in mycobac-
terial peptidoglycan and how these 4,3 and 3,3
crosslinking inhibitors work in mycobacteria. Because
mycobacteria have more 3,3 crosslinks than 4,3 cross-
links, we may observe this glycan strand toxicity more
in the presence of 3,3 inhibitors (such as meropenem),
unlike the situation in E. coli.
Discussion
In this study, we characterize the crystal structure of
the transpeptidase domain of PonA1, which affects
antibiotic tolerance in mycobacteria. The structural
comparison of inhibitor-free and inhibitor-bound
states indicates that binding of penicillin V induces
conformational changes of the loop b40-a3 leading to a
widening of the penicillin-binding pocket. In the struc-
ture, penicillin V forms a network of interactions with
PonA1 residues of highly conserved motifs (SxxK,
SxN, and KTG) in known b-lactam PBPs. These find-
ings highlight why penicillins are such effective inhibi-
tors of this class of enzymes.
Our antibiotic profiling experiments suggest that
PonA1’s transpeptidase activity is important for nor-
mal cellular tolerance of transpeptidase inhibitors,
especially to penicillin V and meropenem. We also
observed that cells that lack PonA1’s transpeptidase
activity grown in the presence of penicillin V exhibit a
substantial delay in growth and develop resistance in
25 h. This may suggest that homologous peptidogly-
can synthesizing enzymes more insensitive to penicillin
V take over PonA1’s function to promote new pepti-
doglycan synthesis or that mutations occurred that
alter the PBP binding affinity of penicillin V. More-
over, our data indicate that meropenem and penicillin
V affect cell growth differently. This may be correlated
with the ability of these classes of compounds to target
4,3 crosslinking enzymes vs. 3,3 crosslinking enzymes.
For example, meropenem is thought to target both the
enzyme groups, whereas carbenicillin or penicillin V
should target just the 4,3 crosslinking enzymes.
In addition, the FTS assays show that different
derivatives of b-lactam antibiotics have different effects
on PonA1 protein stability. The presence of merope-
nem, clavulanate, or nafcillin induces unstable confor-
mations of the protein, while carbenicillin, penicillin V,
hetacillin, dicloxacillin have positive effects on protein
stability. There is a possibility that binding of merope-
nem, clavulanate, or nafcillin increases more disor-
dered conformations of the protein. The initial
noncovalent complexes should have favorable interac-
tions. When the covalent complex is formed and the
serine is acylated, the interactions with product
change. The covalent adducts with the acylated serine
make more unfavorable interactions at the protein
active site that destabilize the structure. We also sug-
gest that, when compared to acylation with penicillin
V, acylation with meropenem may affect the formation
of the disulfide bond, which could lead to a more
unstable conformation of the PonA1 transpeptidase
domain. We found that binding of penicillin V induced
conformational changes in the loop b40-a3 with the
two cysteines (C386 and C389). The changes in the
transpeptidase domain consequently may disturb con-
tacts between PonA1 and its interactors, such as the
endopeptidase RipA, which are important for normal
peptidoglycan metabolism [23]. It has been shown that
the C-terminal 259 residues of the transpeptidase
domain of PonA1, where the last 55 residues form an
unstructured proline-rich tail, are required for interac-
tions with the 25 C-terminal residues of RipA thus
contributing to peptidoglycan remodeling processes
[20]. Our combined data suggest that meropenem
could be a useful model for future drug design to tar-
get mycobacterial PBPs. Alternatively, TB treatment
could be served by further optimization of meropenem
to improve its efficacy and render it even less suscepti-
ble to beta-lactamase cleavage [10].
In conclusion, because M. tuberculosis is an impor-
tant human pathogen, these data provide clear molecu-
lar details toward understanding the mechanism
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underlying the development of penicillin resistance.
These structural data provide a template to design
novel transpeptidase inhibitors and improve already
known drugs to treat TB disease.
Experimental procedures
Cloning
The gene encoding PonA1 (NCBI accession code
YP_177687.1) containing residues 92–676 excluding N-
terminal signal peptide was amplified from the genomic
DNA of M. tuberculosis strain H37Rv using PCR forward
and reverse primers: 50-TACTTCCAATCCAATGCCAAC
AACCTGTTCGGCGGCGAT and 50-TTATCCACTTCC
AATGTTACGGCGTGGGAGTCGCAG, respectively.
The product was cloned into the pMCSG73 vector, which
incorporates a T7 promoter, TVMV-cleavable N-terminal
NusA tag, TEV-cleavable N-terminal hexa-histidine tag,
and StrepII tag developed at Midwest Center of Structural
Genomics (www.mcsg.anl.gov). The vector was transformed
into E. coli BL21(DE3) Magic cells.
Expression and purification
PonA1 fusion protein with NusA was expressed in 4 L of
High Yield selenomethionine M9 medium (Medicilon Inc.,
Shanghai, China) containing 100 mgL1 ampicillin and
50 mgL1 kanamycin. BL21-Magic cells were overgrown
at 37 °C until OD600 reached 0.6–0.8 and were induced
with 5 mM isopropyl b-D-thiogalactoside (IPTG) overnight
at 22 °C. Cells were harvested by centrifugation at 10 876 g
for 10 min and resuspended in lysis buffer pH 8.3 contain-
ing 0.25 M sodium chloride, 0.1 M ammonium sulfate,
43.6 mM sodium phosphate dibasic, 3.25 mM citric acid,
10% glycerol, 1 mM tris-(2-chloroethyl)-phosphate (TCEP),
5 mM imidazole, and 0.08% n-dodecyl b-D-maltoside
(DDM). The cells were then sonicated and the cleared
lysate was prepared by centrifugation at 36 000 g for
40 min at 4 °C. The NusA fusion protein in pMCSG73
constructs is removed before purification by TVMV pro-
tease cleavage. TVMV protease was expressed the same
way as PonA1 fusion protein and cleared lysate was
obtained. The two cleared lysates were mixed together in
5 : 1 ratio (PonA1–NusA:TVMV protease), 5 mM b-mer-
captoethanol was added, and the mixture was incubated
overnight at 4 °C. The protein was purified by Ni-affinity
chromatography followed by gel filtration. Loading buffers
(10 mM Tris/HCl pH 8.3, 0.5 M sodium chloride, 1 mM
TCEP) containing 25 mM and 0.5 M imidazole, respectively,
were used for washing and elution. The purity of acquired
protein was examined with SDS/PAGE and Coomassie
blue staining. SDS/PAGE revealed that the protein showed
a tendency to degrade. An additional chromatographic step
was performed to improve purity. Protein was loaded on a
Ni column, washed with loading buffer containing 0.1 mM
DDM, 1 M sodium chloride, 1 mM TCEP, and eluted with
0.5 M imidazole in loading buffer with 0.5 M sodium chlo-
ride. It was then dialyzed against buffer containing 10 mM
Tris/HCl pH 8.3, 0.5 M sodium chloride, and 1 mM TCEP.
The hexa-histidine tag was cleaved overnight at 4 °C by
recombinant TEV protease having a noncleavable histidine
tag. PonA1 was separated from TEV protease by passing
through the Ni column. Purified PonA1 was concentrated
to 16 mgmL1 in the loading buffer defined above for
crystallization.
Crystallization and data collection
Crystallization trays of selenomethionine-labeled PonA1
were set up on Corning 96-well sitting-drop plates using
the sitting-drop vapor-diffusion method at 19 °C. One
microlitre of protein solution (concentration 8 mgmL1)
was mixed with 1 lL of reservoir solution from the crystal
screens Classics, Classics II, JCSG+, PACT, PEGs, and
PEGs II (Qiagen Inc., Valencia, CA, USA). Prior to
cocrystallization with antibiotic, PonA1 was incubated with
5 mM penicillin V for 30 min. Crystals of PonA1 in inhibi-
tor-free form were obtained with a reservoir solution con-
taining 0.2 M lithium chloride, 0.1 M HEPES buffer pH 7.0,
and 20% (w/v) PEG6000. The cocrystals of PonA1 with
penicillin V were obtained with a reservoir solution con-
taining 0.1 M HEPES buffer pH 7.5 and 25% (w/v)
PEG3350. Before data collection, cocrystals of PonA1 with
antibiotic were soaked with 10 mM penicillin V for 10 min in
5 lL of well solution. All crystals were flash cooled in liquid
nitrogen using reservoir solution as a cryo-protectant. Low
temperature (100 K) X-ray diffraction data were collected at
LS-CAT 21ID-G and 21ID-F beamlines of the Advanced
Photon Source (Argonne National Laboratory, Argonne, IL,
USA) from crystals of PonA1 in inhibitor-free form and in
the presence of penicillin V at 1.8 and 1.75 A resolutions,
respectively. The crystal space groups and cell parameters are
summarized in Table 1.
Structure determination and refinement
The structure of the PonA1 inhibitor-free form was deter-
mined using the single wavelength anomalous dispersion
method (SAD) and the AutoSol Wizard from the PHENIX
program suite [36]. AutoSol contains HYSS [37], SOLVE/RE-
SOLVE [38], XTRIAGE, and PHENIX.REFINE scripts to determine
Se positions, generate experimental phases, build and refine
model structure. The structure of PonA1 in complex with
penicillin V was determined by molecular replacement using
PHASER [39]. The structure of the inhibitor-free form was
taken as the starting model. The structure of the PonA1
inhibitor-bound form was processed in HKL-3000 [40].
Structures were refined in REFMAC [41] and manually built
in COOT [42]. Water molecules were placed using ARP/WARP
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[43] and manually checked in COOT [42]. The quality of
structures was checked using the PDB ADIT validation ser-
ver (http://deposit.pdb.org/validate/) and MOLPROBITY [44].
Refinement and validation statistics are summarized in
Table 1. The figures were generated with PYMOL [45],
CCP4MG [46], LIGPLOT+ [47], and ESPRIPT 3.0 [48].
PDB accession codes
Atomic coordinates and structure factors of PonA1 in inhi-
bitor-free form and in penicillin V-bound form are
deposited into the Protein Data Bank [49] with accession
codes 5CRF and 5CXW, respectively.
Fluorescence thermal shift assay
Fluorescence thermal shift assays were conducted in 384-
well plate format with an assay volume of 10 lL. Concen-
trated PonA1 protein sample and 50009 Sypro Orange
(Invitrogen, Carlsbad, CA, USA) were diluted and mixed
in a Hepes buffer (100 mM HEPES, 150 mM NaCl, pH7.5),
resulting in protein assay concentration of 2.8 lM and 59
Sypro Orange. After adding the protein Sypro Orange mix
to a PCR plate, antibiotics from 10 mM DMSO stocks of
the spectrum collection (MicroSource Discovery Systems,
Gaylordsville, CT, USA) were added in nanoliter volumes
using a Labcyte Echo550 acoustic liquid transfer robot for
testing. The assay plates were mixed with a plate shaker,
sealed with optical clear plastic seal, and centrifuged. Ther-
mal scanning coupled with fluorescence detection was per-
formed on a Bio-Rad CFX384 qPCR machine at
1.5 °Cmin 1 from 10 °C to 80 °C. Data analysis was per-
formed using the in-house software excelFTS which uses
IDBS XLfit for fitting the fluorescence data to a Boltzmann
function to determine the melting temperature Tm and
other thermal transition parameters. The experiments were
performed in triplicate.
Site-directed mutagenesis
Transpeptidase active site mutants were generated as previ-
ously described [15]. The M. smegmatis mutant is S468/
469A (using the appropriate start site for the enzyme, see
[15])—both serines in the canonical SSxK motif were
mutated to alanine to ensure that activity would be abol-
ished. For M. tuberculosis, the mutations are S487/488A.
The mutations were generated in single copy with vectors
that integrate into the L5 phage site in the genome (in
M. smegmatis, pMC1s TetO MSMEG_6900-FLAG; or in
M. tuberculosis pMC1s TetO Rv0050-FLAG) in back-
ground strains where endogenous ponA1 was deleted. The
FLAG epitope does not compromise PonA1 function [15],
as this form of the protein fully complements bacterial
growth by OD assay.
Antibiotic profiling experiments
The single copy mutant strains described above were used
for all experiments. Isogenic wild-type controls (wherein
wild-type ponA1 is integrated at the same L5 phage site and
endogenous ponA1 is deleted) were included for all experi-
ments, along with untreated cells. ForM. tuberculosis experi-
ments, log phase M. tuberculosis H37Rv strains were back-
diluted to a calculated OD600 of 0.01 and grown in
7H9 + OADC complete medium  antibiotic for 6 days in
Table 1. Data collection, structure determination, and refinement
statisticsa.
Inhibitor-free
form
Penicillin V-
bound form
Crystal parameters
Resolution (A) 30.0–1.8 (1.83–1.8) 30.0–1.75 (1.78–1.75)
Space group P21 P212121
Unit cell parameters
a, b, c (A) 46.0, 333.3, 47.5 47.3, 60.6, 133.9
a, b, c (°) 90, 108.4, 90 90, 90, 90
Matthews coefficient
(A3/Da)
1.81 2.17
Solvent content (%) 31.9 43.2
Data collection
Completeness (%) 96.8 (97.6) 99.5 (99)
No. of unique
reflections
120754 39656
I /r(I) 30.3 (2.4) 23.5 (3.1)
Rmerge (%) 0.07 (0.5) 0.09 (0.6)
CC1/2 0.99 (0.79) 0.99 (0.87)
Redundancy 4.9 (4.1) 7.2 (7.1)
Wilson B-factor (A2) 43.9 16.3
Refinement
R (%)/Rfree (%) 16.1/20.5 14.7/18.9
RMSD bond
length (A)
0.014 0.016
RMSD bond
angle (°)
1.6 1.7
Average B value (A2) 31.9 20.1
Number of
molecules in AU
4 1
No. of atoms
Protein 11251 2834
Inhibitor/other
ligands
–/25 24/21
Water molecules 964 458
Ramachandran analysisb
Favored (%)/n 95.4/ 97.2/
Allowed (%)/n 4.2/43 2.8/28
Outlier (%)/n – –
a Data for the highest resolution shell are given in parentheses.
The abbreviations RMSD and AU stand for root-mean-square devia-
tion and asymmetric unit, respectively.
b Defined by validation program MOLPROBITY.
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24-well plates. Cells were grown at 37 °C with shaking. Each
strain was cultured in triplicate. Control wells contained no
antibiotic. Optical density of each well was measured after
6 days. Triplicate wells treated with antibiotic were averaged
and then normalized to the average of triplicate untreated
wells to calculate the percent survival in the presence of
antibiotic. Carbenicillin (1 lgmL 1) was cotreated with
clavulanate (0.5 lgmL 1). Meropenem was used at
0.15625 lgmL 1. ForM. smegmatis experiments, log phase
M. smegmatis mc2155 strains were back-diluted to a calcu-
lated OD600 of 0.01 and grown in 7H9 + ADC complete
medium  antibiotic for 48 h in 96-well plates. Cells were
grown at 37 °C with shaking. Control wells contained no
antibiotic. Optical density of each well was measured every
30 min. All data were plotted without normalization to
untreated control strains. Cells were treated with penicillin V
at 1, 0.5, and 0.25 lgmL 1 in the presence of 5 lgmL 1
clavulanate (cultured in triplicate) or meropenem at 2.5,
1.25, and 0.625 lgmL 1 (cultured in duplicate).
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